Silesian scientists have developed new compounds with anticancer activity

Researchers from the University of Silesia and the Silesian University of Technology have developed new organic compounds from the quinolinic acid group that can be used in anticancer drugs. Before they can be potentially marketed, they still need m.In. in vivo studies.

Previous in vitro studies have shown that certain derivatives of acid quinaldinecarboxylic acids show anticancer activity without damaging healthy cells rek.

A news release from the University of Silesia’s press office says that the combination of these systems with sugar units has helped improve biocompatibility and parameter in the pharmacokinetic of the new compounds, as well as to increase their activity. The results are patent-protected acid glycoconjugates in quinoline.

Syndrome ł scientist from the University of Silesia under the direction of Dr. hab. Robert Musiol of the Department of Organic Chemistry studied quinoline derivatives. These are xenobiotics, which re do not occur naturally in the human body – and are not produced by it. Therefore, it was necessary to find a solution as to how they can be introduced into the human body so that they are not rejected.

– Carbohydrates are subject to metabolic processes in the human body, so we decided to combine the compounds we obtained in just with sugar units. This has improved the biocompatibility of the new substance – m in cited by the university Musiol. He added that the xenobiotic combined with a sugar derivative and introduced into the patient’s body e.g. In pill form, it remains by this organism "unnoticed", so it can reach the affected area.

As the researchers pointed out, the compounds obtained by combining them in organic glycoconjugates acid In quinolinium, it has higher anti-cancer activity than other compounds studied by the team ł substance; pharmacokinetic parameters are also better.

Acid glycoconjugates in quinoline were tested mainly not on com cancerous tumors located in the large intestine. – The special protein structures present there, which re absorb glucose from the food mass, represent, according to scientists into an excellent space for compounds in which The compounds are composed of sugar units. They will be absorbed by the body, while the "released" acid derivatives in quinaldynecarboxylic acids will start the process of destroying com cancerous – reported the researchers.

The results of these studies will be used by scientists for further in-depth analyses already conducted in an in vivo environment. This is another step ahead of the potential introduction of compounds The invention is the next step before the potential introduction of these compounds into the pharmaceutical market.

In addition, in the near future, the researchers plan to Also studying more compounds in this type in terms of increasing anticancer activity, improving the way they are obtained and improving the parameters of the in pharmacokinetic.

As reported by the University of Silesia, tw The inventors of the invention are Dr. Ing. Gabriela Pastuch-Gawołek of the Department of Chemistry at the Silesian University of Technology, as well as scientists affiliated with the University of Silesia – from the Department of Organic Chemistry: Ph. Maciej Serda, Ph.D., Wioleta Cieślik, Ph. Robert Musiol and Prof. zw. Ph. Eng. Jarosław Polański and from the Department of Solid State Physics: Dr. Anna Mrozek-Wilczkiewicz and prof. zw. dr hab. Alicja Ratuszna.